Aspargo Laboratories develops an oral suspension technology for erectile dysfunction that enhances absorption rates and bioavailability compared to traditional tablets. Their product, ASP-001, is a liquid formulation of sildenafil that offers a user-friendly administration method, addressing the challenges faced by patients who have difficulty swallowing pills.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients with erectile dysfunction find traditional tablets inconvenient due to slow absorption rates, the need for planning around meals, and difficulty swallowing pills. This can lead to decreased spontaneity and adherence to treatment.
Solution
Aspargo Laboratories develops oral suspension and spray formulations of existing medications to improve drug delivery and patient experience. Their lead product, ASP-001, is a sildenafil oral spray designed for faster absorption compared to tablets. The oral spray formulation allows for increased discretion, eliminates the need for water, and bypasses the need to coordinate dosing with food intake. By optimizing the interplay between molecular particle size, coating, and viscosity, Aspargo Labs aims to enhance drug delivery, improve patient adherence, and offer more personalized medicine.
Target Audience
The primary target audience includes adult men experiencing erectile dysfunction, physicians seeking to improve patient adherence and treatment outcomes, and pharmaceutical companies looking to expand their product portfolios with innovative drug delivery systems.
Features
- Oral spray formulation for rapid absorption, with initial absorption observed within 5 minutes
- Bioavailability optimized through suspension technology, enhancing the uptake of active ingredients
- Precise, metered dosing for personalized regimens
- User-friendly administration, especially beneficial for patients who have difficulty swallowing tablets
- Convenient application method that does not require water or food intake
- Potential for improved patient adherence due to ease of use and increased spontaneity
- Applicability across various therapeutic areas, including both Rx and OTC products